30-day FRN

Federal Register / Vol. 81, No. 78 / Friday, April 22, 2016 / Notices
Dated: April 18, 2016.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.

Dated: April 18, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.

[FR Doc. 2016–09314 Filed 4–21–16; 8:45 am]

[FR Doc. 2016–09316 Filed 4–21–16; 8:45 am]

BILLING CODE 4140–01–P

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

National Institutes of Health

National Institute of General Medical
Sciences; Notice of Closed Meeting

Submission for OMB Review; 30-Day
Comment Request; The Framingham
Heart Study (NHLBI)

mstockstill on DSK4VPTVN1PROD with NOTICES

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Research Centers in Trauma, Burn and
Perioperative Injury.
Date: May 6, 2016.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, Room 3An. 12N, 45 Center
Drive, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Brian R. Pike, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3AN18, Bethesda, MD
20892, 301–594–3907, [email protected].
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)

VerDate Sep<11>2014

19:18 Apr 21, 2016

Jkt 238001

Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on 12/31/2015,
pages 81830–81832. No comment s were
received. The purpose of this notice is
to allow an additional 30 days for public
comment. The National Heart, Lung and
Blood Institute (NHLBI), National
Institutes of Health, may not conduct or
sponsor, and the respondent is not
required to respond to, an information
collection that has been extended,
revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, OIRA_submission@
omb.eop.gov or by fax to 202–395–6974,
Attention: NIH Desk Officer.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30-days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Ms. Deshiree Belis, National
Heart, Lung, and Blood Institute,
National Institutes of Health, 6705
Rockledge Dr., Suite 6185A, Bethesda,
SUMMARY:

PO 00000

Frm 00062

Fmt 4703

Sfmt 4703

23735

MD 20892, or call non-toll-free number
301–435–1032, or Email your request,
including your address to
[email protected]. Formal requests
for additional plans and instruments
must be requested in writing.
Proposed Collection: The Framingham
Heart Study, 0925–0216, Revision,
National Heart, Lung, and Blood
Institute (NHLBI), the National
Institutes of Health (NIH).
Need and Use of Information
Collection: This proposal is to extend
the Framingham Study to examine the
Generation Three Cohort, New Offspring
Spouses and Omni Group 2 Cohort, as
well as to continue to monitor the
morbidity and mortality which occurs
in all Framingham Cohorts. The
contractor, with the collaborative
assistance of NHLBI Intramural staff,
will invite study participants, schedule
appointments, administer examinations
and testing, enter information into
computer databases for editing, and
prepare scientific reports of the
information for publication in
appropriate scientific journals. All
participants have been examined
previously and thus the study deals
with a stable, carefully described group.
Data are collected in the form of an
observational health examination
involving such components as blood
pressure measurements, venipuncture,
electrocardiography and a health
interview, including questions about
lifestyles and daily living situations.
The National Heart, Lung, and Blood
Institute uses the results of the
Framingham Study to: (1) Characterize
risk factors for cardiovascular and lung
diseases so that national prevention
programs can be designed and
implemented; (2) evaluate trends in
cardiovascular diseases and risk factors
over time to measure the impact of
overall preventive measures; and (3)
understand the etiology of
cardiovascular and lung diseases so that
effective treatment and preventive
modalities can be developed and tested.
Most of the reports of study results have
been published in peer reviewed
medical journals and books.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
8,382.
Estimated Annualized Burden Hours

E:\FR\FM\22APN1.SGM

22APN1

23736

Federal Register / Vol. 81, No. 78 / Friday, April 22, 2016 / Notices
TABLE A.12–1.1—ESTIMATE OF RESPONDENT BURDEN, ORIGINAL COHORT ANNUALIZED
Type of respondent

I. Participant Components Annual Follow-Up:
a. Records Request (Attach #5) .......................................................................
b. Health Status Update (Attach #3) ................................................................

Number of
respondents

Number of
responses per
respondent

30
30

1
1

Sub-Total: Participant Components ..........................................................
II. Non-Participant Components:
A. Informant Contact (Pre-exam and Annual Follow-up) (Attach #3—pages
3–7) ...............................................................................................................
B. Health Care Provider Records Request (Annual follow-up) (Attach #5) .....

* 30

Sub-Total: Non-Participant Components ...................................................

45

Total: Participant and Non-Participant Components .................................

75

Average time
per response
(in hours)

Total annual
burden hour

15/60
15/60

8
8
15

15
30

1
1

10/60
15/60

3
8
10

75

25

* Number of participants as reflected in Row I.b. above.

TABLE A.12–1.2—ESTIMATE OF RESPONDENT BURDEN, OFFSPRING COHORT AND OMNI GROUP 1 COHORT ANNUALIZED
Type of respondent
I. Participant Components Annual Follow-Up:
a. Records Request (Attach #5) .......................................................................
b. Health Status Update (Attach #3) ................................................................
Sub-Total: Participant Components ..........................................................
II. Non-Participant Components:
A. Informant contact (Pre-exam and Annual Follow-up) (Attach #3–pages 3–
7) ...................................................................................................................
B. Health Care Provider Records Request (Annual follow-up) (Attach #5) .....

Number of
respondents

Number of
responses per
respondent

1500
1700
*1700

1
1

15/60
15/60

375
425
800

150
1500

1
1

10/60
15/60

25
375

Sub-Total: Non-Participant Components ...................................................

1650

Total: Participant and Non-Participant Components .................................

3350

Average time
per response
(in hours)

Total annual
burden hour

400
3350

1200

* Number of participants as reflected in Row I.b. above.

TABLE A.12—1.3—ESTIMATE OF RESPONDENT BURDEN, GENERATION 3 COHORT, NOS AND OMNI GROUP 2 COHORT
ANNUALIZED
Type of respondent

mstockstill on DSK4VPTVN1PROD with NOTICES

I. Participant Components:
A. Pre-Exam
1.Telephone contact for appointment .......................................................
2. Exam appointment, scheduling, reminder and instructions (Attach #6)
B. Exam Cycle 3
1. Exam at study center (Attach #1) .........................................................
2. Consent (Attach #10) ............................................................................
2. Home or nursing home visit (Attach #1—partial as respondent is capable) .....................................................................................................
C. Post–Exam
eFHS Mobile Technology for Collection of CVD Risks (Attach #2) .................
D. Annual Follow—Up
1. Records Request (Attach #5) ...............................................................
2. Health Status Update (Attach #3) .........................................................

Number of
respondents

Number of
responses per
respondent

1,450
1,270

1
1

10/60
35/60

242
741

1,200
1,200

1
1

90/60
20/60

1,800
400

35

1

1

35

1,100

18

9/60

2,970

1,200
1,400

1
1

15/60
15/60

300
350

Sub-Total: Participant Components ...................................................
II. Non-Participant Components–Annual Follow-Up:
A. Informant Contacts (Attach #3—pages 3–7) ...............................................
B. Health Care Provider Record Request (Attach #5) .....................................

* 2,850
180
1,155

1
1

Sub-Total: Non-Participant Components ...........................................
Total: Participant and Non-Participant Components .................................

1,335
4,185

28,890

19:18 Apr 21, 2016

Jkt 238001

PO 00000

Frm 00063

Fmt 4703

Sfmt 4703

E:\FR\FM\22APN1.SGM

Total annual
burden hour

6,830

* Number of participants as reflected in Rows I.A.1 and I.D.2 above.

VerDate Sep<11>2014

Average time
per response
(in hours)

22APN1

10/60
15/60

30
289
319
7,157

23737

Federal Register / Vol. 81, No. 78 / Friday, April 22, 2016 / Notices
Estimates of annualized total hour
burden are summarized in Table A.12–
1.4 Below.
Number of
respondents

Type of respondent

Number of
responses per
respondent

Participants ......................................................................................................
Non-Participants ..............................................................................................

4580
3030

1
1

Totals ........................................................................................................

7610

2

Average time
per response
(in hours)

Total annual
burden hour

90/60
15/60

7,653
729
8,382

(Note: reported and calculated numbers differ slightly due to rounding.)
Dated: April 18, 2016.
Valery Gheen,
NHLBI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 2016–09313 Filed 4–21–16; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: The Development of AntiCD70 Chimeric Antigen Receptors
(CARs) for the Treatment of Chronic
Myelogenous Leukemia
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Cancer Institute,
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive patent license to Dedalus
Pharma, LLC (‘‘Dedalus’’) located in
Maryland, USA.

mstockstill on DSK4VPTVN1PROD with NOTICES

SUMMARY:

Intellectual Property
United States Provisional Patent
Application No. 62/088,882, filed
December 8, 2014, entitled ‘‘Anti-CD70
Chimeric Antigen Receptors’’ [HHS
Reference No. E–021–2015/0–US–01];
and PCT Application No. PCT/US2015/
025047 filed April 9, 2015 entitled
‘‘Anti-CD70 Chimeric Antigen
Receptors’’ [HHS Reference No. E–021–
2015/0–PCT–02].
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The patent rights in these inventions
have been assigned to the government of
the United States of America. The
prospective exclusive license territory
may be worldwide and the field of use
may be limited to the development and
commercialization of CD70 chimeric
antigen receptor (CAR)-based
autologous peripheral blood T cell

VerDate Sep<11>2014

20:03 Apr 21, 2016

Jkt 238001

therapy products as set forth in the
Licensed Patent Rights for the treatment
of chronic myelogenous leukemia in
humans.
DATES: Only written comments and/or
applications for a license which are
received by the Technology Transfer
Center at the National Cancer Institute
on or before May 9, 2016 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
Andrew Burke, Ph.D., Licensing and
Patenting Manager, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, MSC 9702,
Rockville, MD 20852; Telephone: (240)
276–5484; Email: [email protected].
SUPPLEMENTARY INFORMATION: The
present invention describes chimeric
antigen receptors (CARs) targeting
CD70. CARs are hybrid proteins
comprised of extracellular antigen
binding domains and intracellular
signaling domains designed to activate
the cytotoxic functions of CARtransduced T cells upon antigen
stimulation.
CD70 is a co-stimulatory molecule
that provides proliferative and survival
cues to competent cells upon binding to
its cognate receptor, CD27. Its
expression is primarily restricted to
activated lymphoid cells; however,
recent research has demonstrated that
several cancers, including renal cell
carcinoma, glioblastoma, non-Hodgkin’s
lymphoma, and chronic myelogenous
leukemia also express CD70 under
certain circumstances. Due to its limited
expression in normal tissues, CARs
targeting CD70 may be useful in
adoptive cell therapy protocols for the
treatment of select cancers.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404. The
prospective exclusive license may be
granted unless within fifteen (15) days
from the date of this published notice,
the NCI receives written evidence and

PO 00000

Frm 00064

Fmt 4703

Sfmt 4703

argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license in
an appropriate field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: April 18, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2016–09324 Filed 4–21–16; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; The Agricultural
Health Study: A Prospective Cohort
Study of Cancer and Other Diseases
Among Men and Women in Agriculture
(NIEHS)
Under the provisions of
section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH), has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on November 27,
2015, Pages 74115–74116, and allowed
60-days for public comment. No public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment. The
National Institute of Environmental
Health Sciences (NIEHS), National
Institutes of Health, may not conduct or
sponsor, and the respondent is not
required to respond to, an information

SUMMARY:

E:\FR\FM\22APN1.SGM

22APN1